Key Takeaways
- Revenue growth: Q3 2026 total revenue rose 2.1% YoY to €67.7 M (≈$75.6 M). Adjusted for the divestiture of RapidFit and Eyewear, organic growth was 4.9%.
- Profit pressure: Net profit slipped to €1.38 M (‑25% YoY) and adjusted EBITDA fell to €8.05 M, driven by higher R&D spend and a soft software franchise.
- Medical dominance: The Medical division generated €36.5 M, a 9.7% increase, representing ≈54% of total sales, but its EBITDA margin fell from 30.6% to 27.4%.
- Manufacturing rebound: Aerospace & defense revenue rose modestly, indicating the start of a recovery after a 2025 slowdown.
- Guidance unchanged: Despite the profit dip, Materialise kept its FY 2026 revenue and EBITDA outlook intact.
Materialise Q3 2026 Overview
Materialise (Euronext Brussels / Nasdaq: MTLS) posted a mixed third‑quarter performance. While top‑line figures edged higher, the bottom line was squeezed by rising costs and a weaker software segment. The company’s strategic focus on personalized medical solutions continues to drive the bulk of its growth, even as it absorbs the short‑term expense of intensified research and development.
Revenue Snapshot
| Segment | Q3 2026 Revenue | YoY Δ% | Adjusted EBITDA | EBITDA Margin |
|---|---|---|---|---|
| Medical | €36.5 M ($40.7 M) | +9.7% | €10.0 M | 27.4% |
| Manufacturing (Aerospace & Defense) | €20.2 M ($22.5 M) | +3.2% | €5.3 M | 26.2% |
| Software | €10.9 M ($12.4 M) | ‑5.8% | €2.8 M | 25.7% |
| Total | €67.7 M ($75.6 M) | +2.1% | €8.05 M | 11.9% |
Figures are rounded; EBITDA margins are calculated on an adjusted basis.
Medical Division – Growth With a Cost Premium
The Medical business now accounts for just over half of Materialise’s total revenue. Its 9.7% top‑line increase was powered by expanding demand for patient‑specific implants, surgical guides, and biocompatible polymers. However, the division’s EBITDA margin contracted by 3.2 percentage points as R&D outlays rose to €6.2 M, up from €5.1 M a year earlier.
“We are seeing real momentum in personalized clinical solutions and have accelerated investments to scale adoption,” said CEO Brigitte de Vet‑Veithen during the earnings call.
Key product launches in Q3 included:
- An upgraded CMF (cranio‑maxillo‑facial) implant line with integrated lattice structures for faster osseointegration.
- A next‑generation patient‑specific orthopedic guide that reduces surgical time by an average of 12 minutes per case.
- Expansion of the Materialise Health Platform to support remote design collaboration across four new hospital networks.
Manufacturing – Early Signs of Recovery
After a steep 2025 decline, the Manufacturing segment posted modest growth, driven by contracts in aerospace and defense. Revenue rose 3.2%, and the segment’s adjusted EBITDA margin held steady at 26.2%, reflecting improved capacity utilization (up to 78% of the company’s printer fleet) and better pricing on high‑value metal parts.
Software – The Weak Link
Software revenue fell 5.8%, primarily because of delayed renewal cycles for the Materialise Magics suite and slower uptake of the new 3DXpert analytics module. The division’s EBITDA margin slipped to 25.7%, prompting the CFO to flag a 2027 roadmap focused on subscription‑based pricing and AI‑enhanced design automation.
Comparison: Medical vs. Manufacturing Profitability
| Metric | Medical | Manufacturing |
|---|---|---|
| Revenue Share | 54% | 30% |
| YoY Revenue Growth | +9.7% | +3.2% |
| Adjusted EBITDA | €10.0 M | €5.3 M |
| EBITDA Margin | 27.4% | 26.2% |
| R&D Intensity (R&D/Revenue) | 17.0% | 9.5% |
The table highlights that while Medical delivers higher absolute earnings, its profitability is more sensitive to R&D spend than Manufacturing.
Bottom Line
Materialise’s Q3 2026 results illustrate a classic growth‑profit trade‑off. The Medical division’s rapid expansion—now responsible for more than half of total sales—confirms the company’s strategic bet on personalized healthcare, but the accompanying R&D surge depresses short‑term margins. Manufacturing shows tentative recovery, whereas Software remains a drag on earnings. By maintaining its full‑year guidance, Materialise signals confidence that the current investment phase will translate into stronger profitability in 2027, provided that software renewal rates improve and manufacturing capacity continues to rise.
